Studies markers that may show how severe eosinophilic granulomatosis with polyangiitis is
Looks for new biological markers to measure disease severity in people with EGPA.
Plain-language title generated from the registry record
Registry title: Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Key facts
- Where
- Boston, Cleveland, Denver, Philadelphia, Pittsburgh, Rochester, Salt Lake City, and San Diego, United StatesSee the 8 sites
Where in United States
- Brigham and Women's HospitalBoston, United StatesNo longer taking part
- Cleveland Clinic FoundationCleveland, United StatesNo longer taking part
- National Jewish HealthDenver, United StatesNo longer taking part
- University of PennsylvaniaPhiladelphia, United StatesNo longer taking part
- University of PittsburghPittsburgh, United StatesNo longer taking part
- Mayo ClinicRochester, United StatesNo longer taking part
- University of UtahSalt Lake City, United StatesNo longer taking part
- University of California San DiegoSan Diego, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT00315380
- Record updated
- 28 August 2026
- Original description
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.Read full original descriptionShow less
Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.
Inclusion: Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study; Parent or guardian willing to provide informed consent, if applicable.
Exclusion: Inability to give informed consent and to sign the consent form.